February 8, 2021

Novocure Announces Addition to Its Board of Directors

Timothy J. Scannell, President and Chief Operating Officer of Stryker Corporation, elected to board of directors ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) has announced an addition to its board of directors. Timothy J. Scannell, an experienced executive leader, was elected to Novocure’s board on Feb. 5. “We… Read More
learn more
January 11, 2021

Novocure Announces Fourth Quarter and Full Year 2020 Preliminary Net Revenues and Provides Company Update

Full year 2020 preliminary net revenues of $494.4 million, representing annual growth of 41 percent compared to 2019 Novocure to present at the 39th Annual J.P. Morgan Virtual Healthcare Conference at 8:20 a.m. EST on Tuesday, Jan. 12, 2021 Fourth quarter and full year 2020 financial results… Read More
learn more
December 23, 2020

Novocure to Participate in the 39th Annual J.P. Morgan Virtual Healthcare Conference

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on January 11 through January 14, 2021. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 8:20 a.m. EST on January 12, 2021. Read More
learn more
December 14, 2020

Novocure Announces National Reimbursement in Switzerland for Optune® in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of Remedies and Equipment (MiGeL) for the treatment of patients with newly diagnosed glioblastoma (GBM), effective April 1, 2021. The List of Remedies… Read More
learn more
December 10, 2020

First Patient Enrolled in Novocure’s Global Phase 3 TRIDENT Trial of Optune® Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma

TRIDENT will test the potential survival benefit of initiating Optune concurrent with radiation therapy in patients with newly diagnosed glioblastoma Preclinical studies demonstrate that Tumor Treating Fields increase sensitivity to radiation therapy and inhibit DNA damage repair ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the first… Read More
learn more
November 25, 2020

Novocure to Participate in the Evercore ISI 2020 Virtual HealthCONx Conference

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that Novocure’s Executive Chairman William Doyle and Chief Science Officer Dr. Uri Weinberg will participate in the 3rd Annual Evercore ISI 2020 Virtual HealthCONx Conference on December 1 through December 2, 2020. Mr. Doyle and Dr. Weinberg will take part in… Read More
learn more
November 19, 2020

Novocure Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual Meeting

Presentations on Tumor Treating Fields cover a broad and growing range of topics, with nearly 85 percent of presentations prepared by external authors ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields will be featured at the Society for Neuro-Oncology 2020 Virtual… Read More
learn more
November 11, 2020

Novocure Receives CE Mark for NovoTTF-100L™ System

The application of CE mark enables Novocure to commercialize the NovoTTF-100L System as a treatment for Malignant Pleural Mesothelioma in the European Union and Switzerland ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer,… Read More
learn more
November 10, 2020

Novocure Announces Agenda for Virtual Research and Development Day

Event will review two decades of Tumor Treating Fields research and introduce exciting new directions of ongoing research and development ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the agenda for the company’s virtual Research and Development Day for analysts and investors from 7:30 a.m. to 9:30 a.m. Read More
learn more
November 9, 2020

Novocure Announces Closing of $150 Million Revolving Credit Facility with a Syndicate of Relationship Banks

Provides flexible capital structure prior to anticipated period of significant innovation and growth ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, today announced the closing of a new $150 million senior secured revolving… Read More
learn more